A study published the 23rd February 2012 on New England Journal of Medicine (N Engl J Med 2012; 366:707-714), shows that Velmurafenib (Zelboraf), a drug approved by the U.S. Food and Drug Administration in 2011, double survival of patients affected by advanced melanoma BRAF V600 Mutant. In a large group of patients survival approached 16 months, which is far beyond what we have seen in other trials; 14 percent of patients failed to show any response to Zelboraf.
Read the article: Survival in BRAF V-600-Mutant Adbvanced Melanoma Treated with Vemurafenib
